MT-4561 / Tanabe Pharma - LARVOL DELTA

a novel BRD4 degrader, MT-4561, demonstrates potent synergy with venetoclax and azacitidine in vitro and significantly prolonged survival in an AML disseminated mouse model (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Acute Myelogenous Leukemia • Oncology • BRD4

A study of MT-4561 in patients with various advanced solid tumors (NCT06943521). (ASCO 2026) - P1/2 | "Ooike S, et al. PB069, Poster Session, 36th EORTC-NCI-AACR Symposium, 2024."

Clinical • Metastases • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Cervical Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • NUT Midline Carcinoma • Oncology • Ovarian Cancer • Prostate Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Targeted Protein Degradation • Urothelial Cancer • BRD4 • DDB1

Strategic evolution of drug discovery modalities: Tanabe Pharma's approach to immunology and oncology (PubMed, Nihon Yakurigaku Zasshi) - "Leveraging insights from the BRD4 inhibitor Y-803, we has developed MT-4561, which demonstrates high degradation activity and antitumor efficacy and is currently in Phase I clinical trials. These efforts exemplify a modality-driven drug discovery approach tailored to disease-specific pathologies, aiming to provide new therapeutic options for intractable diseases through the integration of scientific knowledge and technological innovation."

Journal • Review • Oncology • Targeted Protein Degradation • BRD4 • IL2 • PSMB8

A novel BRD4 degrader, MT-4561, degrades the BRD4-NUT fusion protein in vitro and induces complete tumor regression in a subcutaneous NUT carcinoma xenograft model (AACR-NCI-EORTC 2025) - " In vitro studies: MT-4561 demonstrated potent antitumor activity against Ty-82 cells, a NUT carcinoma cell line harboring the BRD4-NUT fusion protein, and showed greater efficacy than the BET inhibitor JQ1. MT-4561 exhibited potent antitumor efficacy against NUT carcinoma in both in vitro and in vivo studies. Notably, MT-4561 demonstrated activity not only against BRD4-NUT cells but also against BRD3-NUT cell lines. This effect is considered to be mediated through suppression of c-MYC (expression)."

Preclinical • NUT Midline Carcinoma • Oncology • BRD3 • BRD4 • MYC • NUTM1

A Study of MT-4561 in Patients With Various Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Mitsubishi Tanabe Pharma America Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Breast Cancer • Cervical Cancer • Endocrine Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer